Syros Pharmaceuticals, Inc. (SYRS) 10-Year Financial Performance & Capital Metrics

SYRS • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology

AboutSyros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.Show more

Revenue $10M -33.2%
EBITDA -$127M +4.6%
Net Income -$165M -73.9%
EPS (Diluted) -5.81 +22.4%
Gross Margin 77.33% -3.4%
EBITDA Margin -1275.52% -42.8%
Operating Margin -1298.19% -42.2%
Net Margin -1656.34% -160.4%
ROE -227.95% -156.4%
ROIC -
Debt/Equity 3.73 +648.6%
Interest Coverage -25.16 +23.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 37.1%
✓Trading at only 0.0x book value

✗Weaknesses

✗High debt to equity ratio of 3.7x
✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Weak momentum: RS Rating 15 (bottom 15%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y37.12%

3Y-13.01%

TTM-90.54%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-53.44%

EPS CAGR

10Y-

5Y-

3Y-

TTM-32.68%

ROCE

10Y Avg-67.75%

5Y Avg-66.8%

3Y Avg-69.44%

Latest-74.73%

Peer Comparison

Hematologic Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INCYIncyte Corporation	20.66B	105.24	701.60	14.76%	24.69%	25.55%	1.21%	0.01
TGTXTG Therapeutics, Inc.	4.88B	30.71	204.73	40.8%	13.31%	21.87%		1.14
AGIOAgios Pharmaceuticals, Inc.	1.62B	27.80	2.39	36.07%	-8.96%	-31.24%		0.04
CLRBCellectar Biosciences, Inc.	15.48M	3.65	-0.09			-200.99%		0.03
CASICASI Pharmaceuticals, Inc.	21.37M	1.04	-0.41	-15.77%	-183.93%	-301.8%		11.96
VORVor Biopharma Inc.	308.06M	14.06	-0.41			-94.52%		0.33
FATEFate Therapeutics, Inc.	121.12M	1.05	-0.64	-78.55%	-21.87%	-66.69%		0.27
KPTIKaryopharm Therapeutics Inc.	121.95M	6.66	-0.71	-0.55%	-87.43%

Profit & Loss

	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023
Sales/Revenue+	0	317K	317K	1.1M	2.05M	1.98M	15.09M	23.49M	14.88M	9.94M
Revenue Growth %	-	-	0%	2.47%	0.86%	-0.03%	6.62%	0.56%	-0.37%	-0.33%
Cost of Goods Sold+	0	602K	0	1.53M	0	0	0	0	2.97M	2.25M
COGS % of Revenue	-	1.9%	-	1.39%	-	-	-	-	0.2%	0.23%
Gross Profit+	0	-285K	317K	-426K	2.05M	1.98M	15.09M	23.49M	11.91M	7.68M
Gross Margin %	-	-0.9%	1%	-0.39%	1%	1%	1%	1%	0.8%	0.77%
Gross Profit Growth %	-	-	2.11%	-2.34%	5.81%	-0.03%	6.62%	0.56%	-0.49%	-0.35%
Operating Expenses+	13.44M	30.14M	48.28M	55.79M	66.35M	79.72M	97.39M	122.91M	38.81M	30.77M
OpEx % of Revenue	-	95.07%	152.3%	50.67%	32.36%	40.22%	6.45%	5.23%	2.61%	3.1%
Selling, General & Admin	2.51M	5.73M	10.46M	13.89M	16.16M	21.48M	21.32M	23.04M	29.3M	28.28M
SG&A % of Revenue	-	18.07%	33.01%	12.62%	7.88%	10.84%	1.41%	0.98%	1.97%	2.85%
Research & Development	10.92M	24.41M	37.82M	41.9M	50.18M	58.24M	76.06M	99.87M	111.94M	108.15M
R&D % of Revenue	-	77%	119.3%	38.05%	24.48%	29.39%	5.04%	4.25%	7.52%	10.88%
Other Operating Expenses	4K	2K	220K	676K	0	0	0	0	-102.43M	-105.66M
Operating Income+	-13.44M	-29.82M	-47.96M	-54.69M	-64.3M	-77.74M	-82.3M	-99.42M	-135.87M	-128.99M
Operating Margin %	-	-94.07%	-151.3%	-49.67%	-31.36%	-39.22%	-5.45%	-4.23%	-9.13%	-12.98%
Operating Income Growth %	-0.56%	-1.22%	-0.61%	-0.14%	-0.18%	-0.21%	-0.06%	-0.21%	-0.37%	0.05%
EBITDA+	-13.18M	-29.22M	-46.69M	-53.16M	-62.69M	-75.02M	-79.26M	-96.4M	-132.91M	-126.74M
EBITDA Margin %	-	-92.17%	-147.29%	-48.28%	-30.58%	-37.85%	-5.25%	-4.1%	-8.93%	-12.76%
EBITDA Growth %	-0.56%	-1.22%	-0.6%	-0.14%	-0.18%	-0.2%	-0.06%	-0.22%	-0.38%	0.05%
D&A (Non-Cash Add-back)	258K	602K	1.27M	1.53M	1.6M	2.72M	3.04M	3.02M	2.97M	2.25M
EBIT	-13.44M	-29.82M	-47.96M	-54.69M	-62.28M	-75.44M	-82.25M	-82.65M	-90.52M	-159.45M
Net Interest Income+	0	0	0	0	2.02M	2.3M	-1.37M	-3.82M	-2M	1.69M
Interest Income	0	0	0	0	2.02M	2.3M	426K	87K	2.13M	6.82M
Interest Expense	0	0	0	0	1K	0	1.79M	3.91M	4.13M	5.13M
Other Income/Expense	4K	2K	220K	676K	2.02M	2.3M	-1.74M	12.86M	41.22M	-35.59M
Pretax Income+	-13.43M	-29.82M	-47.74M	-54.01M	-62.28M	-75.44M	-84.04M	-86.56M	-94.65M	-164.57M
Pretax Margin %	-	-94.06%	-150.61%	-49.06%	-30.38%	-38.06%	-5.57%	-3.69%	-6.36%	-16.56%
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-13.43M	-29.82M	-47.74M	-54.01M	-62.28M	-75.44M	-84.04M	-86.56M	-94.65M	-164.57M
Net Margin %	-	-94.06%	-150.61%	-49.06%	-30.38%	-38.06%	-5.57%	-3.69%	-6.36%	-16.56%
Net Income Growth %	-0.45%	-1.22%	-0.6%	-0.13%	-0.15%	-0.21%	-0.11%	-0.03%	-0.09%	-0.74%
Net Income (Continuing)	-13.43M	-29.82M	-47.74M	-54.01M	-62.28M	-75.44M	-84.04M	-86.56M	-94.65M	-164.57M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-54.25	-120.45	-37.60	-21.26	-19.07	-18.76	-18.25	-13.84	-7.49	-5.81
EPS Growth %	0.36%	-1.22%	0.69%	0.43%	0.1%	0.02%	0.03%	0.24%	0.46%	0.22%
EPS (Basic)	-54.25	-120.45	-37.60	-21.26	-19.07	-18.76	-18.25	-13.84	-7.49	-5.81
Diluted Shares Outstanding	247.56K	247.56K	1.27M	2.54M	3.27M	4.02M	4.61M	6.25M	12.63M	28.33M
Basic Shares Outstanding	247.56K	247.56K	1.27M	2.54M	3.27M	4.02M	4.61M	6.25M	12.63M	28.33M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023
Total Current Assets+	60.54M	36.45M	85.51M	73.16M	101.73M	114.51M	178.56M	136.59M	211.39M	144.98M
Cash & Short-Term Investments	60.39M	35.91M	83.59M	72.05M	99.68M	91.42M	173.98M	130.37M	202.3M	139.53M
Cash Only	60.39M	35.91M	58.59M	32.2M	49.89M	41.44M	173.98M	92.3M	167.47M	139.53M
Short-Term Investments	0	0	25M	39.84M	49.79M	49.98M	0	38.07M	34.84M	0
Accounts Receivable	0	0	867K	0	0	20.16M	2.33M	2.98M	1.69M	0
Days Sales Outstanding	-	-	998.28	-	-	3.71K	56.37	46.29	41.55	-
Inventory	0	0	0	0	0	290K	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	1.05M	193K	638K	0	0	0	7.39M	5.45M
Total Non-Current Assets+	951K	7.18M	5.82M	5.33M	5.03M	35.47M	34.69M	46.35M	33.09M	23.19M
Property, Plant & Equipment	881K	4.8M	4.85M	3.94M	3.86M	31.89M	29.64M	27.29M	24.66M	19.48M
Fixed Asset Turnover	-	0.07x	0.07x	0.28x	0.53x	0.06x	0.51x	0.86x	0.60x	0.51x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	483K	483K	290K	290K	3.09M	3.09M	13.04M	3.09M	2.12M
Other Non-Current Assets	70K	1.9M	482K	1.1M	881K	490K	1.97M	6.03M	5.35M	1.59M
Total Assets+	61.49M	43.63M	91.32M	78.49M	106.77M	149.98M	213.25M	182.94M	244.49M	168.17M
Asset Turnover	-	0.01x	0.00x	0.01x	0.02x	0.01x	0.07x	0.13x	0.06x	0.06x
Asset Growth %	11.5%	-0.29%	1.09%	-0.14%	0.36%	0.4%	0.42%	-0.14%	0.34%	-0.31%
Total Current Liabilities+	1.25M	7.96M	9.57M	12.41M	19.53M	23.52M	28.62M	31.51M	30.78M	36.68M
Accounts Payable	928K	5.04M	2.42M	2.28M	3.31M	5.85M	3.6M	3.69M	6.41M	11.54M
Days Payables Outstanding	-	3.05K	-	545.71	-	-	-	-	788.68	1.87K
Short-Term Debt	0	0	168K	47K	9K	1.28M	1.73M	0	0	6.67M
Deferred Revenue (Current)	0	0	550K	355K	1000K	1000K	1000K	1000K	1000K	0
Other Current Liabilities	37K	284K	4.36M	7.54M	11.29M	5.19M	3.99M	9.28M	9.44M	6.99M
Current Ratio	48.36x	4.58x	8.94x	5.89x	5.21x	4.87x	6.24x	4.33x	6.87x	3.95x
Quick Ratio	48.36x	4.58x	8.94x	5.89x	5.21x	4.86x	6.24x	4.33x	6.87x	3.95x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	1K	1.63M	1.15M	751K	8.65M	47.28M	94.07M	66.21M	85.97M	114.83M
Long-Term Debt	0	0	0	0	0	0	39.55M	40.26M	40.65M	34.56M
Capital Lease Obligations	0	206K	53K	6K	22K	24.64M	24.93M	22.92M	20.85M	18.53M
Deferred Tax Liabilities	0	0	0	0	-22K	-22.64M	0	0	0	0
Other Non-Current Liabilities	1K	1.42M	1.1M	745K	353K	0	19.71M	3.03M	24.47M	61.75M
Total Liabilities	1.25M	9.58M	10.72M	13.16M	28.18M	70.79M	122.7M	97.72M	116.75M	151.51M
Total Debt+	0	339K	221K	53K	31K	25.92M	66.21M	65.19M	63.57M	62.08M
Net Debt	-60.39M	-35.57M	-58.37M	-32.15M	-49.85M	-15.52M	-107.77M	-27.11M	-103.9M	-77.45M
Debt / Equity	-	0.01x	0.00x	0.00x	0.00x	0.33x	0.73x	0.76x	0.50x	3.73x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-64296.00x	-	-45.92x	-25.45x	-32.87x	-25.16x
Total Equity+	60.24M	34.05M	80.6M	65.32M	78.59M	79.18M	90.55M	85.22M	127.74M	16.66M
Equity Growth %	14.16%	-0.43%	1.37%	-0.19%	0.2%	0.01%	0.14%	-0.06%	0.5%	-0.87%
Book Value per Share	243.34	137.54	63.48	25.71	24.06	19.69	19.66	13.63	10.11	0.59
Total Shareholders' Equity	60.24M	34.05M	80.6M	65.32M	78.59M	79.18M	90.55M	85.22M	127.74M	16.66M
Common Stock	1K	2K	23K	26K	34K	43K	56K	61K	20K	26K
Retained Earnings	-23.7M	-53.51M	-101.26M	-155.27M	-217.54M	-292.98M	-377.02M	-463.58M	-558.23M	-722.81M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-428K	-931K	-9K	-42K	-3K	24K	0	-79K	102K	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023
Cash from Operations+	-11.97M	-23.03M	-40.54M	-44.73M	-40.31M	-60.25M	-57.36M	-99.54M	-123.06M	-109.71M
Operating CF Margin %	-	-72.65%	-127.87%	-40.63%	-19.67%	-30.4%	-3.8%	-4.24%	-8.27%	-11.04%
Operating CF Growth %	-0.66%	-0.92%	-0.76%	-0.1%	0.1%	-0.49%	0.05%	-0.74%	-0.24%	0.11%
Net Income	-13.43M	-29.82M	-47.74M	-54.01M	-62.28M	-75.44M	-84.04M	-86.56M	-94.65M	-164.57M
Depreciation & Amortization	258K	602K	1.27M	1.53M	1.6M	2.72M	3.04M	3.02M	2.97M	2.25M
Stock-Based Compensation	937K	3.23M	4.23M	4.42M	6.61M	9.84M	10.94M	10.35M	11.41M	10.43M
Deferred Taxes	0	0	0	0	0	-1.13M	326K	-16.46M	0	0
Other Non-Cash Items	334K	17K	10K	-102K	-642K	7.24M	2.32M	706K	-37.27M	37.13M
Working Capital Changes	267K	2.94M	1.69M	3.44M	14.39M	-3.48M	10.05M	-10.6M	-5.52M	5.05M
Change in Receivables	0	0	-317K	867K	0	-20.16M	19.99M	7K	1.28M	1.69M
Change in Inventory	0	0	2.69M	3.3M	0	-4.36M	-2.53M	1.98M	-1.28M	0
Change in Payables	334K	2.02M	-404K	141K	888K	1.49M	-1.06M	48K	2.77M	5.13M
Cash from Investing+	-201K	-1.18M	-27.34M	-15.59M	-10.64M	-11.73M	46.66M	-52.65M	67.19M	37.34M
Capital Expenditures	-201K	-1.18M	-2.32M	-821K	-1.38M	-12.64M	-3.34M	-1.25M	-1.24M	-272K
CapEx % of Revenue	-	3.71%	7.32%	0.75%	0.68%	6.38%	0.22%	0.05%	0.08%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	-25.02M	-14.77M	9K	0	0	0	0	1.56M
Cash from Financing+	68.76M	-278K	90.56M	33.94M	69.08M	65.99M	142.95M	70.51M	131.04M	43.46M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	68.76M	0	395K	1.8M	626K	374K	1.3M	439K	11.66M	257K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-12.17M	-24.21M	-42.86M	-45.55M	-41.7M	-72.89M	-60.7M	-100.78M	-124.31M	-109.98M
FCF Margin %	-	-76.36%	-135.2%	-41.37%	-20.34%	-36.78%	-4.02%	-4.29%	-8.35%	-11.07%
FCF Growth %	-0.51%	-0.99%	-0.77%	-0.06%	0.08%	-0.75%	0.17%	-0.66%	-0.23%	0.12%
FCF per Share	-49.16	-97.78	-33.76	-17.93	-12.77	-18.12	-13.18	-16.12	-9.84	-3.88
FCF Conversion (FCF/Net Income)	0.89x	0.77x	0.85x	0.83x	0.65x	0.80x	0.68x	1.15x	1.30x	0.67x
Interest Paid	0	0	0	0	2K	72K	1.5M	0	0	0
Taxes Paid	0	0	0	0	7K	29K	7K	0	0	0

Key Ratios

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Return on Equity (ROE)	-41.83%	-63.25%	-83.28%	-74.02%	-86.55%	-95.63%	-99.02%	-98.49%	-88.9%	-227.95%
Return on Invested Capital (ROIC)	-100762.5%	-	-347.32%	-148.05%	-155.8%	-126.22%	-265.81%	-364.72%	-248.71%	-
Gross Margin	-	-89.91%	100%	-38.69%	100%	100%	100%	100%	80.06%	77.33%
Net Margin	-	-9406.31%	-15060.88%	-4905.54%	-3038%	-3806.16%	-556.8%	-368.52%	-636.12%	-1656.34%
Debt / Equity	-	0.01x	0.00x	0.00x	0.00x	0.33x	0.73x	0.76x	0.50x	3.73x
Interest Coverage	-	-	-	-	-64296.00x	-	-45.92x	-25.45x	-32.87x	-25.16x
FCF Conversion	0.89x	0.77x	0.85x	0.83x	0.65x	0.80x	0.68x	1.15x	1.30x	0.67x
Revenue Growth	-	-	0%	247.32%	86.19%	-3.32%	661.5%	55.62%	-36.65%	-33.23%

Frequently Asked Questions

Growth & Financials

Syros Pharmaceuticals, Inc. (SYRS) reported $0.4M in revenue for fiscal year 2023.

Syros Pharmaceuticals, Inc. (SYRS) saw revenue decline by 33.2% over the past year.

Syros Pharmaceuticals, Inc. (SYRS) reported a net loss of $97.8M for fiscal year 2023.

Dividend & Returns

Syros Pharmaceuticals, Inc. (SYRS) has a return on equity (ROE) of -227.9%. Negative ROE indicates the company is unprofitable.

Syros Pharmaceuticals, Inc. (SYRS) had negative free cash flow of $100.1M in fiscal year 2023, likely due to heavy capital investments.

US Stock Screener

...

Syros Pharmaceuticals, Inc. (SYRS) 10-Year Financial Performance & Capital Metrics

SYRS • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology

Revenue $10M -33.2%
EBITDA -$127M +4.6%
Net Income -$165M -73.9%
EPS (Diluted) -5.81 +22.4%
Gross Margin 77.33% -3.4%
EBITDA Margin -1275.52% -42.8%
Operating Margin -1298.19% -42.2%
Net Margin -1656.34% -160.4%
ROE -227.95% -156.4%
ROIC -
Debt/Equity 3.73 +648.6%
Interest Coverage -25.16 +23.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 37.1%
✓Trading at only 0.0x book value

✗Weaknesses

✗High debt to equity ratio of 3.7x
✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Weak momentum: RS Rating 15 (bottom 15%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y37.12%

3Y-13.01%

TTM-90.54%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-53.44%

EPS CAGR

10Y-

5Y-

3Y-

TTM-32.68%

ROCE

10Y Avg-67.75%

5Y Avg-66.8%

3Y Avg-69.44%

Latest-74.73%

Peer Comparison

Hematologic Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INCYIncyte Corporation	20.66B	105.24	701.60	14.76%	24.69%	25.55%	1.21%	0.01
TGTXTG Therapeutics, Inc.	4.88B	30.71	204.73	40.8%	13.31%	21.87%		1.14
AGIOAgios Pharmaceuticals, Inc.	1.62B	27.80	2.39	36.07%	-8.96%	-31.24%		0.04
CLRBCellectar Biosciences, Inc.	15.48M	3.65	-0.09			-200.99%		0.03
CASICASI Pharmaceuticals, Inc.	21.37M	1.04	-0.41	-15.77%	-183.93%	-301.8%		11.96
VORVor Biopharma Inc.	308.06M	14.06	-0.41			-94.52%		0.33
FATEFate Therapeutics, Inc.	121.12M	1.05	-0.64	-78.55%	-21.87%	-66.69%		0.27
KPTIKaryopharm Therapeutics Inc.	121.95M	6.66	-0.71	-0.55%	-87.43%

Profit & Loss

	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023
Sales/Revenue+	0	317K	317K	1.1M	2.05M	1.98M	15.09M	23.49M	14.88M	9.94M
Revenue Growth %	-	-	0%	2.47%	0.86%	-0.03%	6.62%	0.56%	-0.37%	-0.33%
Cost of Goods Sold+	0	602K	0	1.53M	0	0	0	0	2.97M	2.25M
COGS % of Revenue	-	1.9%	-	1.39%	-	-	-	-	0.2%	0.23%
Gross Profit+	0	-285K	317K	-426K	2.05M	1.98M	15.09M	23.49M	11.91M	7.68M
Gross Margin %	-	-0.9%	1%	-0.39%	1%	1%	1%	1%	0.8%	0.77%
Gross Profit Growth %	-	-	2.11%	-2.34%	5.81%	-0.03%	6.62%	0.56%	-0.49%	-0.35%
Operating Expenses+	13.44M	30.14M	48.28M	55.79M	66.35M	79.72M	97.39M	122.91M	38.81M	30.77M
OpEx % of Revenue	-	95.07%	152.3%	50.67%	32.36%	40.22%	6.45%	5.23%	2.61%	3.1%
Selling, General & Admin	2.51M	5.73M	10.46M	13.89M	16.16M	21.48M	21.32M	23.04M	29.3M	28.28M
SG&A % of Revenue	-	18.07%	33.01%	12.62%	7.88%	10.84%	1.41%	0.98%	1.97%	2.85%
Research & Development	10.92M	24.41M	37.82M	41.9M	50.18M	58.24M	76.06M	99.87M	111.94M	108.15M
R&D % of Revenue	-	77%	119.3%	38.05%	24.48%	29.39%	5.04%	4.25%	7.52%	10.88%
Other Operating Expenses	4K	2K	220K	676K	0	0	0	0	-102.43M	-105.66M
Operating Income+	-13.44M	-29.82M	-47.96M	-54.69M	-64.3M	-77.74M	-82.3M	-99.42M	-135.87M	-128.99M
Operating Margin %	-	-94.07%	-151.3%	-49.67%	-31.36%	-39.22%	-5.45%	-4.23%	-9.13%	-12.98%
Operating Income Growth %	-0.56%	-1.22%	-0.61%	-0.14%	-0.18%	-0.21%	-0.06%	-0.21%	-0.37%	0.05%
EBITDA+	-13.18M	-29.22M	-46.69M	-53.16M	-62.69M	-75.02M	-79.26M	-96.4M	-132.91M	-126.74M
EBITDA Margin %	-	-92.17%	-147.29%	-48.28%	-30.58%	-37.85%	-5.25%	-4.1%	-8.93%	-12.76%
EBITDA Growth %	-0.56%	-1.22%	-0.6%	-0.14%	-0.18%	-0.2%	-0.06%	-0.22%	-0.38%	0.05%
D&A (Non-Cash Add-back)	258K	602K	1.27M	1.53M	1.6M	2.72M	3.04M	3.02M	2.97M	2.25M
EBIT	-13.44M	-29.82M	-47.96M	-54.69M	-62.28M	-75.44M	-82.25M	-82.65M	-90.52M	-159.45M
Net Interest Income+	0	0	0	0	2.02M	2.3M	-1.37M	-3.82M	-2M	1.69M
Interest Income	0	0	0	0	2.02M	2.3M	426K	87K	2.13M	6.82M
Interest Expense	0	0	0	0	1K	0	1.79M	3.91M	4.13M	5.13M
Other Income/Expense	4K	2K	220K	676K	2.02M	2.3M	-1.74M	12.86M	41.22M	-35.59M
Pretax Income+	-13.43M	-29.82M	-47.74M	-54.01M	-62.28M	-75.44M	-84.04M	-86.56M	-94.65M	-164.57M
Pretax Margin %	-	-94.06%	-150.61%	-49.06%	-30.38%	-38.06%	-5.57%	-3.69%	-6.36%	-16.56%
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-13.43M	-29.82M	-47.74M	-54.01M	-62.28M	-75.44M	-84.04M	-86.56M	-94.65M	-164.57M
Net Margin %	-	-94.06%	-150.61%	-49.06%	-30.38%	-38.06%	-5.57%	-3.69%	-6.36%	-16.56%
Net Income Growth %	-0.45%	-1.22%	-0.6%	-0.13%	-0.15%	-0.21%	-0.11%	-0.03%	-0.09%	-0.74%
Net Income (Continuing)	-13.43M	-29.82M	-47.74M	-54.01M	-62.28M	-75.44M	-84.04M	-86.56M	-94.65M	-164.57M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-54.25	-120.45	-37.60	-21.26	-19.07	-18.76	-18.25	-13.84	-7.49	-5.81
EPS Growth %	0.36%	-1.22%	0.69%	0.43%	0.1%	0.02%	0.03%	0.24%	0.46%	0.22%
EPS (Basic)	-54.25	-120.45	-37.60	-21.26	-19.07	-18.76	-18.25	-13.84	-7.49	-5.81
Diluted Shares Outstanding	247.56K	247.56K	1.27M	2.54M	3.27M	4.02M	4.61M	6.25M	12.63M	28.33M
Basic Shares Outstanding	247.56K	247.56K	1.27M	2.54M	3.27M	4.02M	4.61M	6.25M	12.63M	28.33M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023
Total Current Assets+	60.54M	36.45M	85.51M	73.16M	101.73M	114.51M	178.56M	136.59M	211.39M	144.98M
Cash & Short-Term Investments	60.39M	35.91M	83.59M	72.05M	99.68M	91.42M	173.98M	130.37M	202.3M	139.53M
Cash Only	60.39M	35.91M	58.59M	32.2M	49.89M	41.44M	173.98M	92.3M	167.47M	139.53M
Short-Term Investments	0	0	25M	39.84M	49.79M	49.98M	0	38.07M	34.84M	0
Accounts Receivable	0	0	867K	0	0	20.16M	2.33M	2.98M	1.69M	0
Days Sales Outstanding	-	-	998.28	-	-	3.71K	56.37	46.29	41.55	-
Inventory	0	0	0	0	0	290K	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	1.05M	193K	638K	0	0	0	7.39M	5.45M
Total Non-Current Assets+	951K	7.18M	5.82M	5.33M	5.03M	35.47M	34.69M	46.35M	33.09M	23.19M
Property, Plant & Equipment	881K	4.8M	4.85M	3.94M	3.86M	31.89M	29.64M	27.29M	24.66M	19.48M
Fixed Asset Turnover	-	0.07x	0.07x	0.28x	0.53x	0.06x	0.51x	0.86x	0.60x	0.51x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	483K	483K	290K	290K	3.09M	3.09M	13.04M	3.09M	2.12M
Other Non-Current Assets	70K	1.9M	482K	1.1M	881K	490K	1.97M	6.03M	5.35M	1.59M
Total Assets+	61.49M	43.63M	91.32M	78.49M	106.77M	149.98M	213.25M	182.94M	244.49M	168.17M
Asset Turnover	-	0.01x	0.00x	0.01x	0.02x	0.01x	0.07x	0.13x	0.06x	0.06x
Asset Growth %	11.5%	-0.29%	1.09%	-0.14%	0.36%	0.4%	0.42%	-0.14%	0.34%	-0.31%
Total Current Liabilities+	1.25M	7.96M	9.57M	12.41M	19.53M	23.52M	28.62M	31.51M	30.78M	36.68M
Accounts Payable	928K	5.04M	2.42M	2.28M	3.31M	5.85M	3.6M	3.69M	6.41M	11.54M
Days Payables Outstanding	-	3.05K	-	545.71	-	-	-	-	788.68	1.87K
Short-Term Debt	0	0	168K	47K	9K	1.28M	1.73M	0	0	6.67M
Deferred Revenue (Current)	0	0	550K	355K	1000K	1000K	1000K	1000K	1000K	0
Other Current Liabilities	37K	284K	4.36M	7.54M	11.29M	5.19M	3.99M	9.28M	9.44M	6.99M
Current Ratio	48.36x	4.58x	8.94x	5.89x	5.21x	4.87x	6.24x	4.33x	6.87x	3.95x
Quick Ratio	48.36x	4.58x	8.94x	5.89x	5.21x	4.86x	6.24x	4.33x	6.87x	3.95x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	1K	1.63M	1.15M	751K	8.65M	47.28M	94.07M	66.21M	85.97M	114.83M
Long-Term Debt	0	0	0	0	0	0	39.55M	40.26M	40.65M	34.56M
Capital Lease Obligations	0	206K	53K	6K	22K	24.64M	24.93M	22.92M	20.85M	18.53M
Deferred Tax Liabilities	0	0	0	0	-22K	-22.64M	0	0	0	0
Other Non-Current Liabilities	1K	1.42M	1.1M	745K	353K	0	19.71M	3.03M	24.47M	61.75M
Total Liabilities	1.25M	9.58M	10.72M	13.16M	28.18M	70.79M	122.7M	97.72M	116.75M	151.51M
Total Debt+	0	339K	221K	53K	31K	25.92M	66.21M	65.19M	63.57M	62.08M
Net Debt	-60.39M	-35.57M	-58.37M	-32.15M	-49.85M	-15.52M	-107.77M	-27.11M	-103.9M	-77.45M
Debt / Equity	-	0.01x	0.00x	0.00x	0.00x	0.33x	0.73x	0.76x	0.50x	3.73x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-64296.00x	-	-45.92x	-25.45x	-32.87x	-25.16x
Total Equity+	60.24M	34.05M	80.6M	65.32M	78.59M	79.18M	90.55M	85.22M	127.74M	16.66M
Equity Growth %	14.16%	-0.43%	1.37%	-0.19%	0.2%	0.01%	0.14%	-0.06%	0.5%	-0.87%
Book Value per Share	243.34	137.54	63.48	25.71	24.06	19.69	19.66	13.63	10.11	0.59
Total Shareholders' Equity	60.24M	34.05M	80.6M	65.32M	78.59M	79.18M	90.55M	85.22M	127.74M	16.66M
Common Stock	1K	2K	23K	26K	34K	43K	56K	61K	20K	26K
Retained Earnings	-23.7M	-53.51M	-101.26M	-155.27M	-217.54M	-292.98M	-377.02M	-463.58M	-558.23M	-722.81M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-428K	-931K	-9K	-42K	-3K	24K	0	-79K	102K	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023
Cash from Operations+	-11.97M	-23.03M	-40.54M	-44.73M	-40.31M	-60.25M	-57.36M	-99.54M	-123.06M	-109.71M
Operating CF Margin %	-	-72.65%	-127.87%	-40.63%	-19.67%	-30.4%	-3.8%	-4.24%	-8.27%	-11.04%
Operating CF Growth %	-0.66%	-0.92%	-0.76%	-0.1%	0.1%	-0.49%	0.05%	-0.74%	-0.24%	0.11%
Net Income	-13.43M	-29.82M	-47.74M	-54.01M	-62.28M	-75.44M	-84.04M	-86.56M	-94.65M	-164.57M
Depreciation & Amortization	258K	602K	1.27M	1.53M	1.6M	2.72M	3.04M	3.02M	2.97M	2.25M
Stock-Based Compensation	937K	3.23M	4.23M	4.42M	6.61M	9.84M	10.94M	10.35M	11.41M	10.43M
Deferred Taxes	0	0	0	0	0	-1.13M	326K	-16.46M	0	0
Other Non-Cash Items	334K	17K	10K	-102K	-642K	7.24M	2.32M	706K	-37.27M	37.13M
Working Capital Changes	267K	2.94M	1.69M	3.44M	14.39M	-3.48M	10.05M	-10.6M	-5.52M	5.05M
Change in Receivables	0	0	-317K	867K	0	-20.16M	19.99M	7K	1.28M	1.69M
Change in Inventory	0	0	2.69M	3.3M	0	-4.36M	-2.53M	1.98M	-1.28M	0
Change in Payables	334K	2.02M	-404K	141K	888K	1.49M	-1.06M	48K	2.77M	5.13M
Cash from Investing+	-201K	-1.18M	-27.34M	-15.59M	-10.64M	-11.73M	46.66M	-52.65M	67.19M	37.34M
Capital Expenditures	-201K	-1.18M	-2.32M	-821K	-1.38M	-12.64M	-3.34M	-1.25M	-1.24M	-272K
CapEx % of Revenue	-	3.71%	7.32%	0.75%	0.68%	6.38%	0.22%	0.05%	0.08%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	-25.02M	-14.77M	9K	0	0	0	0	1.56M
Cash from Financing+	68.76M	-278K	90.56M	33.94M	69.08M	65.99M	142.95M	70.51M	131.04M	43.46M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	68.76M	0	395K	1.8M	626K	374K	1.3M	439K	11.66M	257K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-12.17M	-24.21M	-42.86M	-45.55M	-41.7M	-72.89M	-60.7M	-100.78M	-124.31M	-109.98M
FCF Margin %	-	-76.36%	-135.2%	-41.37%	-20.34%	-36.78%	-4.02%	-4.29%	-8.35%	-11.07%
FCF Growth %	-0.51%	-0.99%	-0.77%	-0.06%	0.08%	-0.75%	0.17%	-0.66%	-0.23%	0.12%
FCF per Share	-49.16	-97.78	-33.76	-17.93	-12.77	-18.12	-13.18	-16.12	-9.84	-3.88
FCF Conversion (FCF/Net Income)	0.89x	0.77x	0.85x	0.83x	0.65x	0.80x	0.68x	1.15x	1.30x	0.67x
Interest Paid	0	0	0	0	2K	72K	1.5M	0	0	0
Taxes Paid	0	0	0	0	7K	29K	7K	0	0	0

Key Ratios

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Return on Equity (ROE)	-41.83%	-63.25%	-83.28%	-74.02%	-86.55%	-95.63%	-99.02%	-98.49%	-88.9%	-227.95%
Return on Invested Capital (ROIC)	-100762.5%	-	-347.32%	-148.05%	-155.8%	-126.22%	-265.81%	-364.72%	-248.71%	-
Gross Margin	-	-89.91%	100%	-38.69%	100%	100%	100%	100%	80.06%	77.33%
Net Margin	-	-9406.31%	-15060.88%	-4905.54%	-3038%	-3806.16%	-556.8%	-368.52%	-636.12%	-1656.34%
Debt / Equity	-	0.01x	0.00x	0.00x	0.00x	0.33x	0.73x	0.76x	0.50x	3.73x
Interest Coverage	-	-	-	-	-64296.00x	-	-45.92x	-25.45x	-32.87x	-25.16x
FCF Conversion	0.89x	0.77x	0.85x	0.83x	0.65x	0.80x	0.68x	1.15x	1.30x	0.67x
Revenue Growth	-	-	0%	247.32%	86.19%	-3.32%	661.5%	55.62%	-36.65%	-33.23%

Frequently Asked Questions

Growth & Financials

Syros Pharmaceuticals, Inc. (SYRS) reported $0.4M in revenue for fiscal year 2023.

Syros Pharmaceuticals, Inc. (SYRS) saw revenue decline by 33.2% over the past year.

Syros Pharmaceuticals, Inc. (SYRS) reported a net loss of $97.8M for fiscal year 2023.

Dividend & Returns

Syros Pharmaceuticals, Inc. (SYRS) has a return on equity (ROE) of -227.9%. Negative ROE indicates the company is unprofitable.

Syros Pharmaceuticals, Inc. (SYRS) had negative free cash flow of $100.1M in fiscal year 2023, likely due to heavy capital investments.